Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This clinical trial is evaluating a drug called BT5528 alone and in combination with
nivolumab in participants with advanced solid tumors that are identified as positive for
EphA2 expression. The main goals of this study are to:
- Find the recommended dose of BT5528 that can be given safely to participants alone and
in combination with nivolumab
- Learn more about the side effects of BT5528
- Learn more about BT5528 therapy alone and in combination with nivolumab.